DK2892547T3 - Dominant, negativ tnf-alpha-hæmmer til anvendelse i behandling af neurologiske cns-forstyrrelser - Google Patents
Dominant, negativ tnf-alpha-hæmmer til anvendelse i behandling af neurologiske cns-forstyrrelser Download PDFInfo
- Publication number
- DK2892547T3 DK2892547T3 DK13766804.2T DK13766804T DK2892547T3 DK 2892547 T3 DK2892547 T3 DK 2892547T3 DK 13766804 T DK13766804 T DK 13766804T DK 2892547 T3 DK2892547 T3 DK 2892547T3
- Authority
- DK
- Denmark
- Prior art keywords
- neurological
- dominant
- treatment
- cns disorders
- alpha inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699230P | 2012-09-10 | 2012-09-10 | |
| US201361826922P | 2013-05-23 | 2013-05-23 | |
| PCT/US2013/059071 WO2014040076A1 (en) | 2012-09-10 | 2013-09-10 | Methods of treating neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2892547T3 true DK2892547T3 (da) | 2020-10-26 |
Family
ID=50237700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13766804.2T DK2892547T3 (da) | 2012-09-10 | 2013-09-10 | Dominant, negativ tnf-alpha-hæmmer til anvendelse i behandling af neurologiske cns-forstyrrelser |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11365229B2 (da) |
| EP (2) | EP2892547B1 (da) |
| DK (1) | DK2892547T3 (da) |
| ES (1) | ES2825999T3 (da) |
| WO (1) | WO2014040076A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014040076A1 (en) | 2012-09-10 | 2014-03-13 | Xencor | Methods of treating neurological diseases |
| WO2016078672A1 (en) * | 2014-11-21 | 2016-05-26 | Syddansk Universitet | Tnf-alpha inhibitor for treating stroke |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| AU2016371907B2 (en) | 2015-12-18 | 2021-03-04 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Cancer prevention and therapy by inhibiting soluble tumor necrosis factor |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
| JP7085528B2 (ja) | 2017-03-17 | 2022-06-16 | 株式会社ダイヘン | 溶接用センサ装置 |
| WO2020097150A1 (en) * | 2018-11-06 | 2020-05-14 | Virginia Commonwealth University | Treatment of traumatic brain injury |
| US20230135030A1 (en) | 2018-11-26 | 2023-05-04 | Baseline Global, Inc. | Methods, Systems, and a Kit for Diagnosis, Detection, Monitoring & Treatment of Traumatic Brain Injury |
| CN110205294B (zh) * | 2019-04-26 | 2021-05-28 | 青岛大学 | 原代星形胶质细胞/原代中脑腹侧神经元共培养体系在星形胶质细胞与神经元间铁代谢研究中的应用 |
| EP4204094A1 (en) | 2020-08-27 | 2023-07-05 | Enosi Therapeutics Corporation | Methods and compositions to treat autoimmune diseases and cancer |
| WO2022056493A1 (en) * | 2020-09-14 | 2022-03-17 | INmune Bio, Inc. | Biomarker driven methods for treating major depressive disorder |
| WO2023183623A1 (en) * | 2022-03-25 | 2023-09-28 | Regenxbio Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5215743A (en) | 1988-04-13 | 1993-06-01 | Maninder Singh | Tumor necrosis factor formulations |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5576201A (en) | 1994-01-14 | 1996-11-19 | Alexion Pharmaceuticals, Inc. | Retroviral vector particles for transducing non-proliferating cells |
| US5833948A (en) | 1995-06-15 | 1998-11-10 | Bracco Research S.A. | Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant |
| US6177077B1 (en) * | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| US7446174B2 (en) | 2001-03-02 | 2008-11-04 | Xencor, Inc. | Protein based TNF-α variants for the treatment of TNF-α related disorders |
| US7662367B2 (en) * | 2000-03-02 | 2010-02-16 | Xencor, Inc. | Pharmaceutical compositions for the treatment of TNF-α related disorders |
| US7244823B2 (en) * | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
| US7687461B2 (en) * | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
| CA2506031A1 (en) | 2002-11-15 | 2004-06-03 | Vib Vzw | Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof |
| US7642340B2 (en) * | 2003-03-31 | 2010-01-05 | Xencor, Inc. | PEGylated TNF-α variant proteins |
| US9445990B2 (en) * | 2010-10-06 | 2016-09-20 | Medtronic, Inc. | TNF inhibitor formulation for use in implantable infusion devices |
| US9701019B2 (en) | 2011-09-15 | 2017-07-11 | Convergent Information Technologies Gmbh | System and method for the automatic generation of robot programs |
| ES2741897T3 (es) | 2012-02-13 | 2020-02-12 | Radius Eng Inc | Cartucho reutilizable para moldeo por inyección |
| WO2014040076A1 (en) | 2012-09-10 | 2014-03-13 | Xencor | Methods of treating neurological diseases |
-
2013
- 2013-09-10 WO PCT/US2013/059071 patent/WO2014040076A1/en active Application Filing
- 2013-09-10 EP EP13766804.2A patent/EP2892547B1/en active Active
- 2013-09-10 EP EP20178121.8A patent/EP3738605A1/en active Pending
- 2013-09-10 ES ES13766804T patent/ES2825999T3/es active Active
- 2013-09-10 US US14/427,279 patent/US11365229B2/en active Active
- 2013-09-10 DK DK13766804.2T patent/DK2892547T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| US20150239951A1 (en) | 2015-08-27 |
| WO2014040076A1 (en) | 2014-03-13 |
| EP2892547B1 (en) | 2020-08-12 |
| ES2825999T3 (es) | 2021-05-17 |
| EP3738605A1 (en) | 2020-11-18 |
| EP2892547A1 (en) | 2015-07-15 |
| US11365229B2 (en) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2892547T3 (da) | Dominant, negativ tnf-alpha-hæmmer til anvendelse i behandling af neurologiske cns-forstyrrelser | |
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3811943T3 (da) | Forbindelse til anvendelse til behandling af øjenlidelser | |
| DK2919796T3 (da) | Brug af akkermansia til behandling af stofskiftesygdomme | |
| DK3076967T3 (da) | Fremgangsmåder til behandling af residuelle symptomer på skizofreni | |
| IL239355A0 (en) | Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders | |
| DK2961410T3 (da) | Anvendelse af pyrazolopyrimidinderivater til behandlingen af pi3k relaterede lidelser | |
| DK3520805T3 (da) | Sammensætninger til behandling af myelofibrose | |
| DK3305317T3 (da) | Forbindelser til behandling af neuropsykiatriske forstyrrelser | |
| DK3040336T3 (da) | Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande | |
| DK2818241T3 (da) | Fremgangsmåde til fremstilling af behandlingsapparat udstyret med katalysatorbærende honeycombstruktur | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| HK1206721A1 (en) | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders cns 2--23-- | |
| DK2782566T3 (da) | L-serin til anvendelse ved behandling af neurodegenerative lidelser | |
| DK2906219T3 (da) | Orvepitant til behandling af kronisk pruritus | |
| DK3646876T3 (da) | Telomeraseinhibitoren imetelstat til behandling af myeloproliferative lidelser og myeloproliferative neoplasmer | |
| DK2807170T3 (da) | Phragmalin-limonoider til behandlingen af seksuel dysfunktion | |
| DK2705847T3 (da) | Sammensætning til behandling af psoriasis | |
| HK1221166A1 (zh) | 炎症性病症的治療 | |
| ITRM20120405A1 (it) | Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac | |
| ITRM20120530A1 (it) | Compounds for use in the treatment of parasitic diseases | |
| PL3087035T3 (pl) | Sposób biocydowego przetwarzania przemysłowych obiegów wodnych | |
| DK3229790T3 (da) | Sammensætninger omfattende mediumkæde triglycerider til anvendelse i behandlingen af epilepsi | |
| DK2734634T3 (da) | Igf-1 til anvendelse til behandling af migræne |